Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9BQC6
UPID:
RT63_HUMAN
Alternative names:
Mitochondrial ribosomal protein 63; Mitochondrial ribosomal protein L57; Ribosomal protein 63, mitochondrial
Alternative UPACC:
Q9BQC6; A2A332
Background:
The Large ribosomal subunit protein mL63, also known as Mitochondrial ribosomal protein 63, Mitochondrial ribosomal protein L57, and Ribosomal protein 63, mitochondrial, plays a crucial role in protein synthesis within mitochondria. Its involvement in the mitochondrial ribosome underscores its importance in cellular energy metabolism and protein production.
Therapeutic significance:
Understanding the role of Large ribosomal subunit protein mL63 could open doors to potential therapeutic strategies. Its pivotal function in mitochondrial protein synthesis makes it a target of interest for addressing mitochondrial disorders and diseases related to protein synthesis dysregulation.